natgillin/translations-raw huggingface dataset:
Based on the review of the data, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that RETISERT could not have been approved for the treatment of chronic non-infectious uveitis.
Na podlagi pregleda podatkov je imel CHMP v času umika vloge določene zadržke in bil začasnega mnenja, da za zdravilo RETISERT ni mogoče odobriti dovoljenja za zdravljenje kroničnega neinfektivnega uveitisa.
Therefore, at the time of the withdrawal, the CHMP's view was that a benefit of RETISERT had not been sufficiently demonstrated and any benefits did not outweigh the identified risks.
Zato je bil v času umika vloge CHMP mnenja, da koristi zdravila RETISERT niso zadostno dokazane in da niso večje od znanih tveganj.
This anti-inflammatory activity was expected to reduce the symptoms of uveitis.
Ta protivnetna aktivnost bi naj po pričakovanjih zmanjševala simptome uveitisa.
RETISERT is an intravitreal implant (inserted into the vitreous humour, the jelly-like fluid in the central chamber of the eye).
Zdravilo RETISERT je intravitrealni vsadek (vstavi se v steklovino, želatini podobno tekočino v osrednji očesni komori).
The application was at day 120 when the company withdrew.
Podjetje je umaknilo vlogo na 120. dan postopka.
What is RETISERT?
Kaj je zdravilo RETISERT?
What was RETISERT expected to be used for?
Za kaj bi se naj zdravilo RETISERT uporabljalo?
How is RETISERT expected to work?
Kako bi naj zdravilo RETISERT delovalo?
It is given as 2 tablets of the appropriate strength once a day with food.
Daje se v obliki dveh tablet ustrezne jakosti enkrat na dan s hrano.
It is used to treat type 2 diabetes in:
Uporablja se za zdravljenje sladkorne bolezni tipa 2 pri:
Further information on Qtrilmet can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/qtrilmet.
Nadaljnje informacije za zdravilo Qtrilmet so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/qtrilmet.
These studies measured the change in HbA1c levels after 24 weeks of treatment.
V teh študijah so bile izmerjene spremembe ravni HbA1c po 24 tednih zdravljenja.
What measures are being taken to ensure the safe and effective use of Qtrilmet?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Qtrilmet?
The HbA1c levels of patients in the studies were at least 8% and treatment was aimed at reducing HbA1c levels to 7% or less.
Ravni HbA1c bolnikov v študijah so bile vsaj 8 %, zdravljenje pa je bilo namenjeno znižanju ravni HbA1c na 7 % ali manj.
Having all three active ingredients in one tablet reduces the number of tablets the patient needs to take and may improve adherence to treatment, which can improve overall management of the disease.
Z vsemi tremi učinkovinami v eni tableti se zmanjša število tablet, ki jih mora vzeti bolnik, prav tako se lahko izboljša upoštevanje predpisanega zdravljenja, s čimer se lahko izboljša splošno obvladovanje bolezni.
Type 2 diabetes is a disease in which the pancreas does not make enough insulin or when the body cannot use insulin effectively.
Sladkorna bolezen tipa 2 je bolezen, pri kateri trebušna slinavka ne tvori dovolj insulina ali pri kateri telo insulina ne more učinkovito izrabiti.
However, reducing doses or interrupting treatment with Qtrilmet is more complicated than using the active ingredients separately.
Vendar je zmanjšanje odmerkov ali prekinitev zdravljenja z zdravilom Qtrilmet bolj zapleteno, kot ločena uporaba posameznih učinkovin.
The Agency decided that Qtrilmet's benefits are greater than its risks and it can be authorised for use in the EU.
Agencija je zaključila, da so koristi zdravila Qtrilmet večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
Insulin is important for controlling how the body converts glucose (a type of sugar) to energy and how the glucose is stored in the body.
Insulin je pomemben za nadzor nad tem, kako telo pretvori glukozo (vrsto sladkorja) v energijo in kako se glukoza shrani v telesu.
Qtrilmet contains three active substances which all work in different ways.
Zdravilo Qtrilmet vsebuje tri učinkovine, ki delujejo na različne načine.
Saxagliptin, a dipeptidyl-peptidase-4 (DPP-4) inhibitor, has been authorised in the EU as Onglyza since 2009.
Saksagliptin, zaviralec dipeptidil-peptidaze-4 (DPP-4), je v EU odobren od leta 2009 kot zdravilo Onglyza.
As for all medicines, data on the use of Qtrilmet are continuously monitored.
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Qtrilmet stalno spremljajo.
Other information about Qtrilmet
Druge informacije o zdravilu Qtrilmet
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Qtrilmet have been included in the summary of product characteristics and the package leaflet.
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Qtrilmet upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
Dapagliflozin has been authorised in the EU as Forxiga since 2012
Dapagliflozin je v EU odobren od leta 2012 kot zdravilo Forxiga.
The European Medicines Agency considered that the combined use of the active ingredients in Qtrilmet produces worthwhile reduction in HbA1c and that all the active ingredients contribute to this effect.
Evropska agencija za zdravila je zaključila, da kombinirana uporaba učinkovin v zdravilu Qtrilmet koristno zmanjša raven HbA1c in da k temu prispevajo vse učinkovine.
Why is Qtrilmet authorised in the EU?
Zakaj je bilo zdravilo Qtrilmet odobreno v EU?
Qtrilmet (metformin / saxagliptin / dapagliflozin)
Qtrilmet (metformin/saksagliptin/dapagliflozin)
What benefits of Qtrilmet have been shown in studies?
Kakšne koristi zdravila Qtrilmet so se pokazale v študijah?
HbA1c (glycosylated haemoglobin) is an indicator of glucose levels in the blood over the previous 2 to 3 months.
HbA1c (glikozilirani hemoglobin) je kazalnik ravni glukoze v krvi v zadnjih dveh do treh mesecih.
Side effects reported with Qtrilmet are carefully evaluated and any necessary action taken to protect patients.
Neželeni učinki, o katerih so poročali pri zdravilu Qtrilmet, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
An overview of Qtrilmet and why it is authorised in the EU
Pregled zdravila Qtrilmet in zakaj je odobreno v EU
What are the risks associated with Qtrilmet?
Kakšna tveganja so povezana z zdravilom Qtrilmet?
Diabetes leads to high levels of glucose in the blood.
Sladkorna bolezen vodi do visokih ravni glukoze v krvi.
• Metformin works mainly by reducing glucose production and reducing its absorption from the gut.
• Metformin deluje predvsem tako, da zavira tvorbo glukoze in zmanjšuje njeno absorpcijo v črevesju.
What is Qtrilmet and what is it used for?
Kaj je zdravilo Qtrilmet in za kaj se uporablja?
Qtrilmet must also not be used in patients with certain kidney, liver or heart problems or metabolic acidosis (build-up of acid in the blood), or in patients with certain conditions that can lead to metabolic acidosis.
Prav tako se ne sme uporabljati pri bolnikih z določenimi težavami z ledvicami, jetri ali srcem ali metabolično acidozo (kopičenjem kisline v krvi) ali pri bolnikih z določenimi obolenji, ki lahko povzročijo metabolično acidozo.
It is available in two strengths of tablets containing: metformin 850 mg, saxagliptin 2.5 mg and dapagliflozin 5 mg; and metformin 1,000 mg, saxagliptin 2.5 mg and dapagliflozin 5 mg.
Na voljo je v tabletah dveh jakosti, ki vsebujejo: 850 mg metformina, 2,5 mg saksagliptina in 5 mg dapagliflozina ter 1 000 mg metformina, 2,5 mg saksagliptina in 5 mg dapagliflozina.
The dose of Qtrilmet is calculated to match the dose of metformin the patient has been taking.
Odmerek zdravila Qtrilmet se izračuna na podlagi odmerka metformina, ki ga jemlje bolnik.
The most common side effects with Qtrilmet (which may affect more than 1 in 10 people) are infections of the nose and throat, hypoglycaemia (low blood sugar) when used with a sulphonylurea and effects on the gut such as nausea (feeling sick), vomiting, diarrhoea, abdominal (tummy) pain and loss of appetite.
Najpogostejši neželeni učinki zdravila Qtrilmet (ki se lahko pojavijo pri več kot 1 od 10 bolnikov) so okužbe nosu in grla, hipoglikemija (nizke ravni sladkorja v krvi), kadar se uporablja v kombinaciji s sulfonilsečnino, in učinki na črevesje, kot so navzeja (siljenje na bruhanje), bruhanje, driska, bolečine v trebuhu in izguba teka.
• Dapagliflozin blocks the action of a protein in the kidneys called sodium-glucose co-transporter 2 (SGLT2).
• Dapagliflozin zavira delovanje beljakovine v ledvicah, imenovane natrij-glukozni soprenašalec 2 (SGLT2).
• adults whose blood sugar is not controlled well enough with metformin combined with either saxagliptin or dapagliflozin (including those also taking a sulphonylurea, another type of diabetes medicine);
• odraslih, katerih krvni sladkor ni zadovoljivo uravnan z metforminom v kombinaciji s saksagliptinom ali dapagliflozinom (vključno s tistimi, ki jemljejo sulfonilsečnino, drugo vrsto zdravila za zdravljenje sladkorne bolezni);
Qtrilmet must not be used in people who are hypersensitive (allergic) to metformin, saxagliptin or dapagliflozin or to any of the other ingredients or in people who have had serious allergic reactions to a DPP-4 inhibitor (medicines similar to saxagliptin) or to a SGLT2 inhibitor (medicines similar to dapagliflozin).
Zdravila Qtrilmet ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) metformin, saksagliptin ali dapagliflozin ali katere koli druge sestavine, ali osebe, ki so imele resne alergijske reakcije na zaviralec DPP-4 (zdravila, podobna saksagliptinu) ali na zaviralec SGLT2 (zdravila, podobna dapagliflozinu).
Three main studies have shown that the combination of metformin, saxagliptin and dapagliflozin was effective at lowering blood glucose in adults with type 2 diabetes.
Tri glavne študije so pokazale, da je kombinacija metformina, saksagliptina in dapagliflozina učinkovita pri zniževanju glukoze v krvi pri odraslih s sladkorno boleznijo tipa 2.
• adults who are already taking metformin, saxagliptin and dapagliflozin.
• odraslih, ki že jemljejo metformin, saksagliptin in dapagliflozin.
• Saxagliptin blocks the breakdown of incretin hormones, which are released after a meal and cause the pancreas to produce insulin.
• Saksagliptin zavira razgradnjo inkretinskih hormonov, ki se sprostijo po obroku in povzročijo, da trebušna slinavka tvori insulin.
For the full list of side effects and restrictions of Qtrilmet, see the package leaflet.
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Qtrilmet glejte navodilo za uporabo.
Qtrilmet is a diabetes medicine that contains the active substances metformin, saxagliptin and dapagliflozin.
Qtrilmet je zdravilo za zdravljenje sladkorne bolezni, ki vsebuje učinkovine metformin, saksagliptin in dapagliflozin.
How is Qtrilmet used?
Kako se zdravilo Qtrilmet uporablja?
How does Qtrilmet work?
Kako zdravilo Qtrilmet deluje?
In the first main study in 534 patients, the combination of metformin, saxagliptin and dapagliflozin reduced average HbA1c by 1.47 percentage points compared with metformin combined with either saxagliptin (0.88 percentage point reduction) or dapagliflozin (1.20 percentage point reduction).
V prvi glavni študiji pri 534 bolnikih je kombinacija metformina, saksagliptina in dapagliflozina znižala povprečno raven HbA1c za 1,47 odstotne točke v primerjavi z metforminom v kombinaciji s saksagliptinom (znižanje za 0,88 odstotne točke) ali dapagliflozinom (znižanje za 1,20 odstotne točke).
The pattern of Qtrilmet's side effects is manageable and similar to that in patients treated with saxagliptin and dapagliflozin added to metformin.
Vzorec neželenih učinkov zdravila Qtrilmet je obvladljiv in podoben vzorcu pri bolnikih, zdravljenih s saksagliptinom in dapagliflozinom, dodanima metforminu.
In the third study in 320 patients, the combination of metformin, saxagliptin and dapagliflozin reduced average HbA1c by 0.82 percentage points compared with a reduction of 0.10 percentage points in patients receiving metformin, saxagliptin and placebo.
V tretji študiji pri 320 bolnikih je kombinacija metformina, saksagliptina in dapagliflozina znižala povprečno raven HbA1c za 0,82 odstotne točke v primerjavi z znižanjem za 0,10 odstotne točke pri bolnikih, ki so prejemali metformin, saksagliptin in placebo.
Qtrilmet can only be obtained with a prescription.
Predpisovanje in izdaja zdravila Qtrilmet je le na recept.
By blocking their breakdown, saxagliptin causes the pancreas to produce more insulin when blood glucose levels are high.
Z zaviranjem njihove razgradnje povzroči, da trebušna slinavka tvori več insulina, ko je raven glukoze v krvi visoka.
In the second study in 315 patients, the combination of metformin, saxagliptin and dapagliflozin reduced average HbA1c by 0.51 percentage points compared with a reduction of 0.16 percentage points in patients receiving metformin, dapagliflozin and placebo (dummy treatment).
V drugi študiji pri 315 bolnikih je kombinacija metformina, saksagliptina in dapagliflozina znižala povprečno raven HbA1c za 0,51 odstotne točke v primerjavi z znižanjem za 0,16 odstotne točke pri bolnikih, ki so prejemali metformin, dapagliflozin in placebo (zdravilo brez učinkovine).
In the first study, the patients had an average of 0.021 serious infections per year.
V prvi študiji so imeli bolniki v povprečju 0,021 resnih okužb na leto.
IgG has been used as a medicine since the 1980s and has a wide range of activity against organisms that can cause infection.
IgG se kot zdravilo uporablja od osemdesetih let preteklega stoletja in ima širok razpon delovanja proti organizmom, ki lahko povzročijo okužbo.
In babies and young children, hereditary fructose intolerance may not yet have been diagnosed and may be fatal; this medicine must therefore not be given to babies and children below two years of age.
Pri dojenčkih in majhnih otrocih fruktozna intoleranca morda še ni bila diagnosticirana in utegne biti usodna, zato se tega zdravila dojenčkom in otrokom, mlajšim od dveh let, ne sme dajati.
In the second study, up to 14 (73%) of the 19 patients who remained in the study had a platelet count above 50 million platelets per millilitre at least once during the study.
V drugi študiji je do 14 (73 %) od 19 bolnikov, ki so ostali vključeni v študijo, imelo koncentracijo trombocitov nad 50 milijonov trombocitov na mililiter vsaj enkrat med študijo.
The main measure of effectiveness was the number of serious bacterial infections over a year's treatment.
Glavno merilo učinkovitosti je bilo število resnih bakterijskih okužb v obdobju enoletnega zdravljenja.
The dose and frequency of infusion depend on the disease being treated, and may need to be adjusted for patients depending on their response.
Odmerek in pogostost infuzije sta odvisna od zdravljene bolezni in ju bo morda treba bolnikom prilagoditi glede na njihov odziv.
The European Commission granted a marketing authorisation valid throughout the European Union for Flebogammadif on 23 August 2007.
Evropska komisija je dovoljenje za promet z zdravilom Flebogammadif, veljavno po vsej Evropski uniji, odobrila dne 23. avgusta 2007.
Since this is below the predefined threshold of one infection per year, this indicates that the medicine is effective in replacing the patient's antibodies.
Ker je ta vrednost nižja od vnaprej določene mejne vrednosti, enake eni okužbi na leto, to kaže, da je zdravilo učinkovito pri nadomeščanju bolnikovih protiteles.
It contains immunoglobulin G (IgG), which is a type of antibody.
Ta vsebuje imunoglobulin G (IgG), ki je vrsta protitelesa.
The main measure of effectiveness was the highest blood platelet level that was achieved during the three-month study.
Glavno merilo učinkovitosti je bila najvišja koncentracija trombocitov v krvi, dosežena med trimesečno študijo.
The full EPAR for Flebogamma DIF can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Flebogamma DIF je na voljo na spletni strani agencije ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
In the first study, involving 46 patients with PID, the medicine was infused every 21 to 28 days.
V prvi študiji, v katero je bilo vključenih 46 bolnikov s sindromom primarne imunske pomanjkljivosti, je bilo zdravilo infundirano vsakih 21 do 28 dni.
They can also be approved for the treatment of patients with Guillain-Barré syndrome, patients with Kawasaki disease and patients undergoing haematopoietic stem cell transplantation, without the need for specific studies in these diseases.
Odobrena so lahko tudi za zdravljenje bolnikov z Guillain-Barréjevim sindromom, bolnikov s Kawasakijevim sindromom ter bolnikov, pri katerih je bila izvedena presaditev krvotvornih matičnih celic, ne da bi bilo treba za te bolezni izvajati posebne študije.
This is a summary of the European public assessment report (EPAR) for Flebogamma DIF.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Flebogamma DIF.
• Guillain-Barré syndrome, which causes multiple inflammations of the nerves in the body;
• Guillain-Barréjevega sindroma, ki povzroča večkratna vnetja živcev v telesu;
Therefore, the CHMP concluded that Flebogamma DIF's benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zato zaključil, da so koristi zdravila Flebogamma DIF večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
Flebogamma DIF is used in patients who need more antibodies in their blood to help fight infections and other diseases.
Zdravilo Flebogamma DIF se uporablja pri bolnikih, ki potrebujejo več protiteles v krvi, da jim pomagajo pri premagovanju okužb in drugih bolezni.
The name of the medicine was changed to Flebogamma DIF on 2 September 2010.
Ime zdravila je bilo 2. septembra 2010 spremenjeno v Flebogamma DIF.
Flebogamma DIF was not compared with any other treatment in either study.
Zdravila Flebogamma DIF v nobeni študiji niso primerjali s kakim drugim zdravljenjem.
• Acquired immune deficiency syndrome (AIDS) in children who contracted HIV from birth and have frequent infections.
• sindroma pridobljene imunske pomanjkljivosti (aidsa) pri otrocih, ki so se z virusom HIV okužili ob rojstvu in imajo pogoste okužbe.
As human normal immunoglobulin has been used to treat these diseases for some time, only two small studies were needed to establish the effectiveness and safety of Flebogamma DIF in patients.
Ker se humani normalni imunoglobulin že dlje časa uporablja za zdravljenje teh bolezni, sta za potrditev učinkovitosti in varnosti zdravila Flebogamma DIF pri bolnikih zadostovali le dve manjši študiji.
For more information about treatment with Flebogamma DIF, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Flebogamma DIF preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
• Hypogammaglobulinaemia (low levels of antibodies) in patients: with chronic lymphocytic leukaemia (a cancer of a type of white blood cell) and frequent bacterial infections after preventive treatment with antibiotics has failed; with multiple myeloma (another cancer of a type of white blood cell) and frequent bacterial infections and in whom vaccination against ‘pneumococcal' bacteria has failed; who have had haematopoietic (blood) stem cell transplantation (when the patient receives stem cells from a matched donor to help restore the bone marrow).
• hipogamaglobulinemije (nizkih ravni protiteles) pri bolnikih: s kronično limfocitno levkemijo (rakom vrste belih krvnih celic) in pogostimi bakterijskimi okužbami po neuspelem preventivnem zdravljenju z antibiotiki; z multiplim mielomom (drugo obliko raka vrste belih krvnih celic) in pogostimi bakterijskimi okužbami po neuspelem cepljenju proti pnevmokoknim bakterijam; s presaditvijo hematopoetskih (krvotvornih) matičnih celic (kadar bolnik prejme matične celice darovalca, ki se ujemajo z njegovimi in pomagajo obnoviti kostni mozeg);
Rarely human normal immunoglobulins may cause a sudden fall in blood pressure and, in a few cases, anaphylactic shock (a severe allergic reaction) even when the patient had no previous allergic reaction to the medicine.
Humani normalni imunoglobulini lahko v redkih primerih povzročijo nenaden padec krvnega tlaka, v posameznih primerih pa anafilaktični šok (hudo alergijsko reakcijo), četudi bolnik pred tem ni imel alergijske reakcije na zdravilo.
Flebogamma DIF is also used to treat certain immune system disorders:
Zdravilo Flebogamma DIF se uporablja tudi za zdravljenje nekaterih motenj imunskega sistema:
Flebogamma DIF must not be used in people who are allergic to normal human immunoglobulin or any of the other ingredients, or in patients who are allergic to other types of immunoglobulin, especially where they have deficiency (very low levels) of immunoglobulin A (IgA) and they have antibodies against IgA.
Zdravila Flebogamma DIF ne smejo uporabljati osebe, ki so alergične na humani normalni imunoglobulin ali katero koli drugo sestavino zdravila, ter bolniki, ki so alergični na druge tipe imunoglobulina, zlasti če imajo pomanjkanje (zelo nizko raven) imunoglobulina A (IgA) ter imajo protitelesa proti IgA.
The medicine must not be used in patients who are intolerant to fructose (a type of sugar).
Zdravila Flebogamma DIF ne smejo uporabljati bolniki, ki ne prenašajo fruktoze (vrste sladkorja).
According to current guidelines, medicines that have been shown to be effective in patients with PID and in patients with ITP can also be approved for use in the treatment of all types of primary immunodeficiency, as well as low antibody levels due to blood cancers and AIDS in children.
V skladu z veljavnimi smernicami je mogoče zdravila, ki so se izkazala kot učinkovita pri bolnikih s sindromom primarne imunske pomanjkljivosti in bolnikih z idiopatsko trombocitopenično purpuro, odobriti tudi za uporabo pri zdravljenju vseh vrst primarne imunske pomanjkljivosti ter tudi nizkih ravni protiteles zaradi krvnega raka ali aidsa pri otrocih.
Flebogamma DIF is given by infusion into a vein by a doctor or nurse, but patients (or their carers) may administer it themselves once they have been trained.
Zdravilo Flebogamma DIF se uporablja kot intravenska infuzija, ki jo daje zdravnik ali medicinska sestra, vendar si ga bolniki lahko dajejo tudi sami (oziroma jim ga dajejo njihovi skrbniki), če so bili ustrezno usposobljeni.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Flebogamma DIF.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Flebogamma DIF, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
The second study looked at using Flebogamma DIF in 20 patients with ITP.
V drugi študiji so proučevali uporabo zdravila Flebogamma DIF pri 20 bolnikih z idiopatsko trombocitopenično purpuro.
It contains the active substance human normal immunoglobulin.
Vsebuje zdravilno učinkovino humani normalni imunoglobulin.
Previously known as Flebogammadif
1 Prej znano kot Flebogammadif.
The active substance in Flebogamma DIF, human normal immunoglobulin, is a highly purified protein extracted from human plasma (part of the blood).
Zdravilna učinkovina zdravila Flebogamma DIF, humani normalni imunoglobulin, je visoko prečiščena beljakovina, pridobljena iz človeške plazme (dela krvi).
What benefit has Flebogamma DIF shown during the studies?
Kakšne koristi je zdravilo Flebogamma DIF izkazalo med študijami?
Flebogamma DIF works by restoring abnormally low IgG levels to their normal range in the blood.
Zdravilo Flebogamma DIF deluje tako, da nenormalno nizko koncentracijo IgG vrne v območje njene normalne vrednosti v krvi.